Positive clinical trial results could significantly expand the market opportunity for Sirtex.
We reduce our fair value estimate for no-moat Sirtex Medical to AUD 15 per share, from AUD 28, following the abbreviated release of long-awaited overall survival, or OS, data rendered by the combined Sirflox/Foxfire/Foxfire Global studies, ahead of the American Society of Clinical Oncology, or ASCO, annual meeting in Chicago next month. The read-out showed no overall survival benefit in adding SIR-Spheres to chemotherapy versus chemotherapy alone in first-line treatment settings for metastatic c...Sirtex Medical is a global life-sciences company based in Australia. Co. is engaged in developing and delivering effective oncology treatments using novel small particle technology. Co.'s main product is a targeted radioactive treatment for liver cancer called SIR-Spheres® Y-90 resin microspheres. SIR-Spheres Y-90 resin microspheres are a medical device used in interventional oncology and delivered to the liver via Selective Internal Radiation Therapy.
Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.
Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.
We have operations in 27 countries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.